NOTICE TO DISREGARD -- GSB GOLD STANDARD BANKING CORPORATION AG
HAMBURG, Germany, April 29, 2021 (GLOBE NEWSWIRE) -- We are advised by GSB GOLD STANDARD BANKING CORPORATION AG that journalists and other readers should disregard the news release, “GSB Group doubts in gold reserves of Karatbars and the V999 Coin as well as the existence of the Osint Group” issued April 28, 2021, over GlobeNewswire.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 202419.4.2024 13:00:00 CEST | Press release
The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual General Meeting is attached. For further information, please contact: Jon Olav Ødegård, CEO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: investor@hofsethbiocare.no About Hofseth BioCare ASA: HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads. Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies ongoing in multiple clinics and university research labs. Lead clinical and pre-clinical candidates are focused on developing an oral treatment for inflammatory disease driven by eosinophils (a type of white blood cell). Clinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers
NetBet Casino slår sig sammen med Stakelogic19.4.2024 12:59:43 CEST | pressemeddelelse
COPENHAGEN, Denmark, April 19, 2024 (GLOBE NEWSWIRE) -- NetBet og Stakelogic har indgået en samarbejdsaftale, som vil bringe Stakelogics spil til NetBets kunder i Danmark. Selvom Stakelogic først blev grundlagt i 2014, har de hurtigt etableret sig som en stor spiller inden for online gaming. Deres omdømme som en nyskaber i branchen er blevet anerkendt, og virksomheden er blevet nomineret til de prestigefyldte kategorier, Industry Innovation of the Year, og Innovation in Casino Entertainment ved SBC Awards 2023. Blandt de mange spil, der er tilgængelige for NetBet Danmarks spillere som et resultat af partnerskabet med Stakelogic, er Book of Cleopatra Super Stake Edition, Volcano Deluxe og Bandits Thunder Link. NetBet Danmarks PR-manager, Claudia Georgevici, udtaler: "Hos NetBet forstår vi vigtigheden af at give vores spillere så mange unikke spil som muligt for at sikre, at de får den bedst mulige spiloplevelse. Stakelogic har et bibliotek af innovative spil, hvilket gør dem til den ide
NetBet Casino joins forces with Stakelogic19.4.2024 12:59:43 CEST | Press release
COPENHAGEN, Denmark, April 19, 2024 (GLOBE NEWSWIRE) -- NetBet and Stakelogic have finalised a collaborative agreement that will bring Stakelogic’s games to NetBet customers in the Danish region. Despite only being founded in 2014, Stakelogic has quickly established themselves as a major player in the world of online gaming. Their reputation as an industry disruptor has been recognised, with the company being shortlisted for the prestigious categories of Industry Innovation of the Year and Innovation in Casino Entertainment at the SBC Awards 2023. Among the many games that are available to NetBet Denmark customers as a result of the partnership with Stakelogic are Book of Cleopatra Super Stake Edition, Volcano Deluxe and Bandits Thunder Link. NetBet Denmark’s PR manager, Claudia Georgevici, said: “At NetBet, we understand the importance of providing our players with as many unique games as possible, to ensure they have the best possible gaming experience. Stakelogic has a library of in
Giambattista Valli dazzles Barcelona during the Bridal Night19.4.2024 12:41:00 CEST | Press release
BARCELONA, Spain, April 19, 2024 (GLOBE NEWSWIRE) -- The most exclusive fashion show of the Barcelona Bridal Fashion Week charmed over 450 guests last night who enjoyed a unique show in the historic building of the Llotja de Mar. The Maison Giambattista Valli exclusively celebrated the runway debut of its bridal collection during the Bridal Night, the gala evening of the event organized by Fira de Barcelona with the support of the Catalan Ministry of Business and Labor. In an extraordinary show, Giambattista Valli's 30 creations shone with their own light. It was a culmination of silhouettes, representing a comprehensive exhibition of Mr. Valli’s concept of contemporary bridal dressing, inviting his audience to witness the manifestation of his vision, translated into a presentation that embodies the essence of individuality, sharing a dream and a celebration and love. The fashion show featured ten dresses from the third “Love Collection,” ten iconic silhouettes from the first and secon
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T